



Extracellular Vesicles as Future Therapeutics and Indicators of Cardiac Disease

Guest Editors:

Dr. Jiacheng Sun

Department of Biomedical Engineering, University of Alabama at Birmingham, Birmingham, AL, USA

Dr. Junjie Yang

Division of Regenerative Medicine, Department of Center for Clinical and Translational Science, Shonan Kamakura General Hospital, Kamakura, Japan

Dr. Yu-An Lu

Department of Biomedical Engineering, University of Alabama at Birmingham, Birmingham, AL, USA

Deadline for manuscript submissions:

closed (30 September 2023)

Message from the Guest Editors

Cardiovascular diseases (CVDs) are the leading cause of mortality and morbidity worldwide. Extracellular vesicles have attracted significant attention in mediating intercellular communication during cardiovascular development and pathophysiology. Exosomal ncRNAs, including microRNAs, lncRNAs, and circRNAs, are considered to be key players, offering a potential source of novel diagnostic and prognostic biomarkers for CVDs.

This Special Issue aims to highlight the novel studies and strategies that might overcome current obstacles in cardiovascular translational medicine and their potential applications.

Specific themes we would like contributors to address include, but are not limited to:

- Extracellular vesicles in cardiac cells differentiation;
- Extracellular vesicles in cardiovascular repair and regeneration;
- Extracellular vesicles in cardiovascular protection;
- Extracellular vesicles in cardiovascular drug development and safety assay;
- Extracellular vesicles in tissue engineering;
- Extracellular vesicles in CVD diagnostic and prognostic;
- Extracellular vesicles in CVD pathogenesis;
- Extracellular vesicles in cardiovascular homeostasis.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research

Learning, Spaulding

Rehabilitation Hospital and

Massachusetts General Hospital,

Harvard Medical School, Boston,

MA 02114, USA

2. Department of Epidemiology,

Harvard T.H. Chan School of

Public Health, Boston, MA 02115,

USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [CAPUS / SciFinder](#), and [other databases](#).

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Contact Us

Biomedicines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](#)